Atreca Inc represents values of collaboration, innovation, and patient-centricity. The company is dedicated to creating transformative therapeutics through its proprietary drug discovery platform. By harnessing the power of the immune system, Atreca aims to develop novel treatments for a range of diseases, including cancer and autoimmune disorders. Atreca's corporate philosophy revolves around partnering with leading academic institutions and biopharmaceutical companies to accelerate the development of breakthrough therapies. With a strong focus on scientific excellence and strategic collaborations, Atreca Inc strives to make a positive and lasting impact on patient lives.

Atreca Inc is primarily present in the United States.

Atreca Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in June 2019, raising approximately $125 million. In 2020, Atreca initiated a Phase 1b clinical trial for its lead product candidate, ATRC-101, in patients with select solid tumor types. Additionally, Atreca expanded its collaborations with global pharmaceutical companies, such as BeiGene, to further advance its discovery platform and accelerate the development of novel therapeutics. The company has consistently demonstrated its commitment to innovation and growth in the field of cancer therapeutics.

Atreca Inc is a biotechnology company founded in 2010. Headquartered in California, the company specializes in developing novel immune-based therapeutics for the treatment of various diseases. Atreca's innovative approach combines proprietary technologies with advanced data science to discover and develop potential drug candidates. The company focuses on identifying targets and generating therapeutic antibodies aimed at addressing unmet medical needs. With a team of experienced scientists and strategic collaborations, Atreca Inc strives to make significant contributions to the field of immunotherapy. By leveraging its expertise and cutting-edge technologies, the company aims to improve patient outcomes and advance the understanding of the immune system.

The main competitors of Atreca Inc in the market include companies such as Agenus Inc, Bristol-Myers Squibb, and Merck & Co. These companies operate in the same biopharmaceutical industry as Atreca Inc, focusing on the development and commercialization of innovative therapies. While Atreca Inc stands out with its unique approach to immunotherapy and drug discovery, it competes against these industry giants to capture market share and draw investors' attention. By diligently conducting research and staying at the forefront of medical advancements, Atreca Inc strives to distinguish itself in this highly competitive landscape.

Atreca Inc is primarily active in the biotechnology and pharmaceutical industries.

Atreca Inc. specializes in the discovery and development of innovative antibody-based therapeutics. The company's business model revolves around leveraging its proprietary drug discovery platform to identify and develop novel monoclonal antibodies with the potential to address a wide range of diseases. By focusing on the human immune response, Atreca aims to uncover and select therapeutically-relevant antibodies that target specific antigens. Through collaborations and partnerships, Atreca further accelerates the development and commercialization of its candidates. With a strong emphasis on precision medicine, Atreca Inc. strives to revolutionize the treatment landscape by harnessing the power of the immune system to combat various illnesses.

מכפיל הרווחים למניה של Atreca הוא ‎-0.11.

מכפיל המכירות של Atreca הוא 0.

תוצאת איכות AlleAktien עבור Atreca היא 2/10.

לא ניתן לחשב כרגע את ההכנסה עבור Atreca.

הרווח של מצופה Atreca הוא ‎-30.33 מיליון USD.

Atreca Inc is a biopharmaceutical company specializing in the development of immunotherapies for cancer and autoimmune diseases. The company uses proprietary technologies and innovative approaches to identify and develop antibodies and other biomolecules that can specifically target and combat disease targets. Atreca's business model is based on the development of therapeutics using its own technology platforms. The company takes a three-pronged approach to utilize its technology platforms, which includes the identification of antibodies, the development of diagnostics, and the combination of therapeutic agents. One of Atreca's key products is its Immune Repertoire Capture (IRC) technology platform, which allows for the identification of antibodies against specific disease targets. IRC utilizes next-generation sequencing technology and bioinformatics to sequence and identify antibodies in the blood samples of patients and healthy donors. Based on this approach, Atreca has built an extensive library of antibodies that can be used for the development of therapeutics and diagnostics. Another important product of Atreca is its platform for the combination of therapeutic agents, which allows for the linking of multiple agents into a single molecule. This technology offers potentially synergistic effects to enhance the efficacy of therapeutics. This platform is currently being used in the clinical phase for cancer. Atreca also pursues a diagnostic strategy, which allows for the identification of disease-specific antibodies and their use as biomarkers for diagnostics and prognostics. This approach utilizes the IRC platform to identify unique antibody profiles for different disease states. The company has already entered partnerships with pharmaceutical companies to utilize their IRC technology for antibody identification and validation. To increase the value of its business model, Atreca has entered into partnerships with other biopharmaceutical companies to utilize its technology platforms for antibody production and the development of cancer therapies. The company also collaborates with several academic institutions to advance scientific progress in immunotherapy. In general, Atreca is a leading company in the field of immunotherapy with a unique technology platform that allows it to work faster and more efficiently than its competitors. Atreca focuses on utilizing its technology platforms to develop new and innovative therapeutics and diagnostics for the treatment of cancer and autoimmune diseases.

Atreca מחלקת דיבידנד בסכום של 0 USD במספר תשלומים במהלך השנה.

לא ניתן לחשב כרגע את הדיבידנד עבור Atreca או שהחברה אינה מפרישה דיבידנד.

ISIN של Atreca היא US04965G1094.

ה-WKN של Atreca הוא A2PLNM.

הטיקר של Atreca הוא BCEL.

במהלך 12 החודשים האחרונים, Atreca שילמה דיבידנד בגובה . זה מקביל לתשואת דיבידנד של כ-. ל-12 החודשים הקרובים, Atreca צפויה לשלם דיבידנד של 0 USD.

תשואת הדיבידנד של Atreca נוכחית היא .

Atreca משלמת דיבידנד רבעוני. הדיבידנד מתבצע בחודשים .

Atreca שילם דיבידנד כל שנה במשך ה-0 שנים האחרונות.

לתקופה הבאה של 12 חודשים ניתן לצפות לדיבידנדים בסך של 0 USD. זה מייצג תשואת דיבידנד של 0 %.

Atreca משויך למגזר 'בריאות'.

כדי לקבל את הדיבידנד האחרון של Atreca מתאריך 19.2.2025 בסך 0 USD, היה עליך להחזיק את המניה לפני היום המוקדם בתאריך 19.2.2025 בתיק.

תשלום הדיבידנד האחרון בוצע ב-19.2.2025.

בשנת 2024 שילמה Atreca 0 USD כדיבידנדים.

הדיבידנדים של Atreca מתחלקים ב-USD.